299 related articles for article (PubMed ID: 33236314)
1. High Incidence of Hepatic Encephalopathy After Viatorr Controlled Expansion Transjugular Intrahepatic Portosystemic Shunt Creation.
Kloster ML; Ren A; Shah KY; Alqadi MM; Bui JT; Lipnik AJ; Niemeyer MM; Ray CE; Gaba RC
Dig Dis Sci; 2021 Nov; 66(11):4058-4062. PubMed ID: 33236314
[TBL] [Abstract][Full Text] [Related]
2. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.
Praktiknjo M; Abu-Omar J; Chang J; Thomas D; Jansen C; Kupczyk P; Schepis F; Garcia-Pagan JC; Merli M; Meyer C; Strassburg CP; Pieper CC; Trebicka J
JHEP Rep; 2021 Jun; 3(3):100264. PubMed ID: 34013182
[TBL] [Abstract][Full Text] [Related]
3. Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation.
Charon JP; Alaeddin FH; Pimpalwar SA; Fay DM; Olliff SP; Jackson RW; Edwards RD; Robertson IR; Rose JD; Moss JG
J Vasc Interv Radiol; 2004 Nov; 15(11):1219-30. PubMed ID: 15525740
[TBL] [Abstract][Full Text] [Related]
4. Transjugular Intrahepatic Portosystemic Shunt Using the New Gore Viatorr Controlled Expansion Endoprosthesis: Prospective, Single-Center, Preliminary Experience.
Miraglia R; Maruzzelli L; Di Piazza A; Mamone G; Caruso S; Gentile G; Tuzzolino F; Floridia G; Petridis I; Volpes R; Luca A
Cardiovasc Intervent Radiol; 2019 Jan; 42(1):78-86. PubMed ID: 30073477
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Occurrence and Risk of Hepatic Encephalopathy After TIPS Creation: A 15-Year Experience.
Coronado WM; Ju C; Bullen J; Kapoor B
Cardiovasc Intervent Radiol; 2020 Aug; 43(8):1156-1164. PubMed ID: 32435836
[TBL] [Abstract][Full Text] [Related]
6. Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft.
Hausegger KA; Karnel F; Georgieva B; Tauss J; Portugaller H; Deutschmann H; Berghold A
J Vasc Interv Radiol; 2004 Mar; 15(3):239-48. PubMed ID: 15028808
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Patency after Transjugular Intrahepatic Portosystemic Shunt Reduction for Overshunting Adverse Events.
Shah RJ; Alqadi MM; Duvvuri M; Kim YJ; Tyagi R; Lokken RP; Gaba RC
J Vasc Interv Radiol; 2022 Dec; 33(12):1507-1512. PubMed ID: 35964879
[TBL] [Abstract][Full Text] [Related]
8. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?
Chung HH; Razavi MK; Sze DY; Frisoli JK; Kee ST; Dake MD; Hellinger JC; Kang BC
J Gastroenterol Hepatol; 2008 Jan; 23(1):95-101. PubMed ID: 18171347
[TBL] [Abstract][Full Text] [Related]
9. Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes.
Casadaban LC; Parvinian A; Minocha J; Lakhoo J; Grant CW; Ray CE; Knuttinen MG; Bui JT; Gaba RC
Dig Dis Sci; 2015 Apr; 60(4):1059-66. PubMed ID: 25316553
[TBL] [Abstract][Full Text] [Related]
10. Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunt procedures.
Maleux G; Nevens F; Wilmer A; Heye S; Verslype C; Thijs M; Wilms G
Eur Radiol; 2004 Oct; 14(10):1842-50. PubMed ID: 15221261
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the curative effect of transjugular intrahepatic portosystemic shunt with expanded polytetrafluoroethylene-covered stent and drug combined with gastroscopy as the secondary prevention of esophageal -gastric variceal bleeding in portal hypertension].
Lin ZP; Chen SL; Wang JY; Liu F; Tan Q; Peng QF; Zhao JB
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):672-678. PubMed ID: 32911906
[No Abstract] [Full Text] [Related]
12. Comparison of specialized stent versus generic stent and bare stent combination for transjugular intrahepatic portosystemic shunt creation.
Bai Y; Liu J; Wang C; Yao W; Ju S; Wang Y; Zhou C; Dong X; Zheng C
Sci Rep; 2024 Jun; 14(1):14439. PubMed ID: 38910214
[TBL] [Abstract][Full Text] [Related]
13. Long-term patency and clinical outcome of the transjugular intrahepatic portosystemic shunt using the expanded polytetrafluoroethylene stent-graft.
Luo X; Zhao M; Wang X; Jiang M; Yu J; Li X; Yang L
PLoS One; 2019; 14(2):e0212658. PubMed ID: 30811467
[TBL] [Abstract][Full Text] [Related]
14. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy.
Pereira K; Carrion AF; Martin P; Vaheesan K; Salsamendi J; Doshi M; Yrizarry JM
Liver Int; 2015 Dec; 35(12):2487-94. PubMed ID: 26332169
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of transjugular intrahepatic portosystemic shunt with Viatorr stent in 43 cases].
Zhou H; Yao X; Tang SH; Xie M; Feng ZS; Qin JP
Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):54-59. PubMed ID: 33541024
[No Abstract] [Full Text] [Related]
16. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts.
Riggio O; Angeloni S; Salvatori FM; De Santis A; Cerini F; Farcomeni A; Attili AF; Merli M
Am J Gastroenterol; 2008 Nov; 103(11):2738-46. PubMed ID: 18775022
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
[TBL] [Abstract][Full Text] [Related]
18. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
[TBL] [Abstract][Full Text] [Related]
19. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage.
Sahagun G; Benner KG; Saxon R; Barton RE; Rabkin J; Keller FS; Rosch J
Am J Gastroenterol; 1997 Sep; 92(9):1444-52. PubMed ID: 9317060
[TBL] [Abstract][Full Text] [Related]
20. Does advanced chronic kidney disease impact transjugular intrahepatic portosystemic shunt efficacy and safety?
Lakhoo J; Gunasekaran SS; Lokken RP; Lipnik AJ; Ray CE; Bui JT; Gaba RC
Acta Gastroenterol Belg; 2017; 80(2):243-248. PubMed ID: 29560689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
